Table 3.

Summary of Secondary Endpoints during Part II

	Naproxen 1000 mg (Part I)/1000 mg (Part II)	Etoricoxib 60 mg (Part I)/60 mg (Part II)	Etoricoxib 60 mg (Part I)/90 mg (Part II)	LS mean difference between etoricoxib 60 mg/90 mg vs. Etoricoxib 60 mg/60 mg; p-Value	Etoricoxib 90 mg (Part I/90 mg (Part II)
Number of Subjects	n = 74	n = 175	n = 178		n = 70
LS Mean Change from Week 6 in Spinal Pain Intensity Over Weeks 10 and 12 (95 % CI) (Inadequate Responders in Part I)	−12.89 (−16.57, −9.20)	−7.26 (−9.73, −4.80)	−9.97 (−12.42, −7.51)	−2.70 (−4.88, −0.52)	−7.69 (−11.48, −3.90)
LS Mean Change from Week 6 in PGART Over Weeks 10 and 12 (95 % CI) (Inadequate Responders in Part I)	0.21 (0.07, 0.35)	0.13 (0.04, 0.23)	0.21 (0.12, 0.30)	0.08 (−0.05, 0.21)	0.28 (0.13, 0.42)
Number of Subjects	n = 141	n = 310	n = 314		n = 140
Time-weighted LS Mean Change from Baseline in Spinal Pain Intensity Over 26 Weeks (95 % CI)	−38.26 (−41.70, −34.83)	−35.07 (−37.41, −32.73)	−36.30 (−38.65, −33.96)	−1.70 (−5.79, 2.39)	−36.76 (−40.22, −33.31)

LS least squares, CI confidence interval, PGART patient global assessment of response to therapy